US Stock MarketDetailed Quotes
OTLK Outlook Therapeutics
- 5.245
- +0.025+0.48%
Trading Oct 2 15:55 ET
124.07MMarket Cap-890P/E (TTM)
5.345High5.150Low128.70KVolume5.210Open5.220Pre Close677.64KTurnover0.95%Turnover RatioLossP/E (Static)23.66MShares18.00052wk High-1.48P/B71.00MFloat Cap4.41652wk Low--Dividend TTM13.54MShs Float219.200Historical High--Div YieldTTM3.74%Amplitude4.004Historical Low5.265Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Outlook Therapeutics Stock Forum
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Outlook Therapeutics has received European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation for treating wet AMD. This makes it the first ophthalmic bevacizumab formulation approved for wet AMD in the EU. This authorization covers all 27 EU Member States and will extend to Icela...
In an era where medical advancements are pivotal to enhancing quality of life, a significant breakthrough has been made in the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss among the elderly. Outlook Therapeutics, Inc. has received a positive opinion from the European Union's Committee for Me...
No comment yet